ONCOLOGY. Vol. 17 No. 5
Hematopoietic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma
By LEONA A. HOLMBERG, MD, PhD
Clinical Research Division
Cancer Research Center
Department of Medicine
University of Washington
School of Medicine
F. MARC STEWART, MD
Clinical Research Division
Cancer Research Center
Professor, Department of Medicine
University of Washington
School of Medicine
Seattle, Washington | May 1, 2003
JOHN W. SWEETENHAM, MD
ANGELO MICHELE CARELLA, MD
1. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non- Hodgkin’s lymphoma. N Engl J Med 333:1540-1545, 1995.
2. Philip T, Chauvin F, Armitage J, et al: Parma international protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77:1587-1592, 1991.
3. Lopez R, Martino R, Sureda A, et al: Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience. Haematologica 84:350-355, 1999.
4. Stein RS, Greer JP, Goodman S, et al: High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant 23:227-233, 1999.
5. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999.
6. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991.
7. Holmberg LA, Boeckh M, Hooper H, et al: Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood 94:4029-4035, 1999.
8. Crippa F, Holmberg L, Carter RA, et al: Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 8:281-289, 2002.
9. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000.
10. Flinn IW, O’Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non- Hodgkin’s lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000.
11. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000.
12. Voso MT, Pantel G, Weis M, et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lymphoma. Br J Haematol 109:729-735, 2000.
13. Brugger W, Hirsch J, Repp R, et al: Multicenter phase II study with Rituximab treatment for follicular and mantle cell lymphoma after high-dose therapy and autologous blood stem cell transplantation (abstract 113). Ann Oncol 13:38, 2002.
14. Horwitz SM, Negrin RS, Stockerl-Goldstein KE, et al: Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive nonhodgkin’s lymphomas (abstract 3578). Blood 98(pt 1):862, 2001.
15. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993.
16. Liu SY, Eary JF , Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti- CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278, 1998.
17. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti- CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000.
18. Vose JM, Bierman PJ, Lynch JC, et al: Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkins lymphoma (NHL): synergistic results with no added toxicity (abstract 19). Proc Am Soc Clin Oncol 20(pt 1):6, 2001.
19. Winter JN, Inwards D, Erwin W, et al: Phase I trial combining 90Y Zevalin and highdose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL (abstract 2835). Blood 98(pt 1):677-678, 2001.
20. Laszlo D, Galieni P, Raspadori D, et al: Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non-Hodgkin lymphoma patients. Leuk Lymphoma 37:157-161, 2000.
21. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 17:3128-3135, 1999.
22. Colombat P, Cornillet P, Deconinck E, et al: Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study. Bone Marrow Transplant 26:971-977, 2000.
23. Tarella C, Caracciolo D, Corradini P, et al: Long-term follow-up of advanced-stage lowgrade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 14:740-747, 2000.
24. Fefer A, Benyunes MC, Massumoto C, et al: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41-45, 1993.
25. Margolin KA, van Besien K, Wright C, et al: Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant 5: 36-45, 1999.
26. Holmberg LA, Rowley SD, Visuthisalechai S, et al: The addition of immunotherapy early in an autologous transplant (abstract 48). Biol Blood Marrow Transplant 6:146, 2000.
27. Holmberg LA, Maloney DG, Bensinger WI: Rituximab and interleukin 2 for CD20 positive non-Hodgkin’s lymphoma following autologous transplant (abstract 2543). Blood 100(pt 1):646-647, 2002.
28. Bensinger WI, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344: 175-181, 2001.
29. Khouri IF, Keating M, Körbling M, et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor- cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817- 2824, 1998.
30. Slattery JT, Clift RA, Buckner CD, et al: Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055-3060, 1997.
31. Dreger P, Glass B, Seyfarth B, et al: Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT. Bone Marrow Transplant 26:1361-1362, 2000.
32. Carella AM, Cavaliere M, Lerma E, et al: Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 18:3918-3924, 2000.
33. Socie G, Stone JV, Wingard JR, et al: Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341:14-21, 1999.
34. Chen F, Maldonado MA, Madaio M, et al: The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol 161:5880-5885, 1998.
35. Couriel DR, Khouri IF, Anderson B, et al: Graft-versus-host disease (GVHD) after nonmyeloablative (NMA) versus myeloablative (MA) conditioning regimens in fully matched sibling donor hematopoietic stem cell transplants (HSCT): An update (abstract 1697). Blood 98(pt 1):404, 2001.
36. Flowers MED, Parker PM, Johnston LJ, et al: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. Blood 100:415-419, 2002.
37. Gopal AK, Rajendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002.
38. Caballero MD, Perez-Simon JA, Iriondo A, et al: High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 14:140-151, 2003.
39. Gianni AM, Bregni M, Siena S, et al: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP- B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297, 1997.
40. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87-2 protocol—a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:3025-3030, 2000.
41. Santini G, Salvagno L, Leoni P, et al: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non- Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 16:2796-2802, 1998.
42. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93:22-30, 2001.
43. Milpied N, Deconninch E, Colombat P, et al: Front line high-dose chemotherapy with autologous stem cell transplantation is not superior to CHOP regimen for adult patients with non-IPI high-risk intermediate IP high grade NHL. Results of a randomized trial by GOELAMS. Ann Oncol 10(suppl 3):77, 1999.
44. Sweetenham JW, Pearce R, Taghipour G, et al: Adult Burkitt’s and Burkitt-like non- Hodgkin’s lymphoma—outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14:2465-2472, 1996.
45. Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS: Tandem transplantation in lymphoma (review). Bone Marrow Transplant 28:529-535, 2001.
Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma
ONCOLOGY, May 15, 2013
Making Good Results Even Better: The Evolving Role of Radiotherapy in Patients With Early Diffuse Large B-Cell Lymphoma
ONCOLOGY, May 15, 2013
Are CML Drugs Priced Out of Reach?
May 2, 2013
46-Year-Old CML Patient Develops Painful Ulceration
Ted Rosen, MD , September 10, 2012
A hematologically stable CML patient developed a solitary, exquisitely painful ulceration, 7 cm × 5 cm, located on the mid-medial foreleg. There was never any evidence of venous insufficiency. The patient denied the possibility of a spider bite. What is the likely cause of this lesion?
SearchMedica Search Result
Find peer-reviewed literature and websites for practicing medical professionals